Fig. 7: Cl-amidine reduced neuroinflammation in CCM.

a, Representative images of the cerebellum of Ccm3-iECKO vehicle-treated mice (upper panel) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹) mice (lower panel) stained with GFAP (magenta) and CX3CR1 (green). Insets with dashed, white line are shown in the magnifications to the right. b, Quantification of GFAP expression in the cerebellum of Ccm3-iECKO vehicle-treated (n = 13) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹; n = 8) mice. c, Quantification of CX3CR1 expression in the cerebellum of Ccm3-iECKO vehicle-treated (n = 13) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹; n = 8) mice. d, Representative images of the cerebellum of Ccm3-iECKO vehicle-treated mice (upper panel) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹) mice (lower panel) stained with DAPI (blue) and Iba1 (green). Insets with dashed, white line are shown in the magnifications to the right. e, Quantification of Iba1 expression in the cerebellum of Ccm3-iECKO vehicle-treated (n = 13) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹; n = 8) mice. f, Representative images of reactive microglia in the cerebellum of Ccm3-iECKO mice stained with DAPI (blue), CD13 (red) and Iba1 (green). Insets with dashed, white line are shown in the magnifications to the right. White arrows represent reactive microglia expressing Iba1 and CD13. g, Quantification of percentage of reactive microglia in the cerebellum of Ccm3-iECKO vehicle-treated (n = 13) and Cl-amidine-treated (10 mg kg⁻¹ d⁻¹; n = 8) mice. Insets (far right) are zoomed-in regions. In the graphs, each data point represents one biological replicate; the bar indicates the median of each group; and the error bars represent the IQR. Statistical significance was determined using a Mann–Whitney U-test (two-tailed). cb, cerebellum.

Source data